Menopause Market (2026 - 2033)

Menopause Market Summary

The global menopause market size was valued at USD 18.7 billion in 2025 and is projected to grow from USD 19.7 billion in 2026 to USD 28.8 billion by 2033, growing at a CAGR of 5.6% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 37.1% in 2025. The market is expected to witness significant growth, driven by demographic shifts and an increasing awareness of the health and wellness needs of aging women.

By 2025, over 1 billion women globally are anticipated to reach menopause, which would make up approximately 12% of the global population. Vasomotor Symptoms (VMS) are experienced by almost 75% of women reaching menopause. According to a menopause study by StatPearls Publishing LLC in December 2023, 1.3 million females aged between 51 and 52 in the U.S. become menopausal every year. Around 5% of females aged 40 and 45 had early menopause symptoms & 1% of women reported premature menopause before the age of 40. 

This can lead to an overall loss of productivity and quality of life, making treatment crucial. This creates a wide population pool to be served by menopause products, such as dietary supplements and Over-the-Counter (OTC) drugs, which can help relieve symptoms, including hot flashes, osteoporosis, night sweats, & vaginal atrophy.

Furthermore, early treatment is expected to reduce the stress of high healthcare expenditure, as females facing VMS lead to an overall burden of USD 660 million globally. In addition, productivity loss accounts for an additional USD 150 million. In addition, menopause triggers other healthcare conditions in females, such as reduced musculoskeletal health and increased risk of cardiovascular diseases. Three major conditions associated with accelerated incidence in menopausal women are hypertension (75%), depression (10%), and osteoporosis (30%).

Night sweats and hot flashes or VMS are key symptoms of Menopausal Transition (MT). In addition, issues such as mood swings, difficulty concentrating, and depression are being linked to menopause. Hot flashes are experienced by around 80% of females during menopause and are characterized by transient chills, anxiety, sweating, & sensations of heat that last for around 1 to 5 minutes. The increasing number of females experiencing the condition, along with the high prevalence of menopausal symptoms, is anticipated to drive the segment's growth. In addition, the increasing aging population across the globe is accelerating market growth.

Moreover, the high cost of prescription medication has led to an increased demand for OTC products, such as vaginal pain & dryness gels and moisturizers, for self-medication. In addition, telehealth consultations have made access to consultations easier and increased access to cheaper over-the-counter drugs that start as low as USD 13 on online websites. Your Menopause Microbiome is an AI startup working to create personalized OTC solutions for menopausal women.

Furthermore, recent innovations in menopause management have introduced several new products aimed at improving symptoms such as hot flashes and night sweats, particularly through non-hormonal approaches. Some notable developments include:

• Bayer is advancing elinzanetant, a dual neurokinin-1 and 3 (NK-1 and NK-3) receptor antagonist, which is currently in late-stage clinical development. This medication targets the root causes of vasomotor symptoms (VMS) associated with menopause. In October 2024, Elinzanetant received New Drug Applications (NDAs) acceptance for review in multiple countries, including the U.S. and EU, indicating a strong potential for market availability.

• In September 2024, Bonafide Health launched Thermella, a first hormone-free, prescription-free NK3 receptor antagonist designed specifically for menopause symptom management. It aims to rebalance the body's thermoregulatory center.

Market Dynamics

The menopause market is experiencing steady growth as women increasingly prioritize healthy aging, hormonal wellness, and quality of life during midlife transitions. Menopause-related products and services are widely used to manage symptoms such as hot flashes, night sweats, mood changes, sleep disturbances, vaginal dryness, and hormonal imbalances. Growing awareness regarding menopause management, increasing acceptance of hormone replacement therapy (HRT), and the expanding availability of specialized solutions—including hormone therapies, dietary supplements, digital health platforms, diagnostic tools, and non-hormonal treatment options are contributing to market expansion. Furthermore, rising healthcare expenditure, increased focus on women's health, technological advancements in personalized care, and growing consumer demand for science-backed wellness solutions are expected to continue driving growth in the Menopause Market.

Market Concentration & Characteristics

The chart below illustrates the relationship between industry concentration, industry characteristics, and industry participants. The x-axis represents the level of industry concentration, ranging from low to high. The y-axis represents various industry characteristics, including industry competition, degree of innovation, impact of regulations, level of merger & acquisition activities, and geographic expansion. The market is highly fragmented, with the presence of various global and regional manufacturers.

The market is experiencing a moderate to high degree of innovation, driven by growing awareness, increasing demand for personalized care, and advancements in pharmaceutical and digital health solutions. In June 2024, ADM and Sirio Pharma introduced a gummy containing soy isoflavones aimed at easing estrogen depletion symptoms. Furthermore, traditional hormone replacement therapies (HRT) are being enhanced to improve safety and efficacy. Moreover, digital health platforms and wearable technologies are emerging to support symptom tracking, teleconsultations, and behavioral health interventions tailored to menopausal women. The integration of artificial intelligence and data analytics into these platforms further enhances personalized treatment approaches.

Several key market players are devising business growth strategies in the form of mergers and acquisitions. Through M&A activity, these companies can expand their business geographies. For instance, in January 2024, Dr. Reddy’s Laboratories Ltd. acquired MenoLabs, a women’s health and dietary supplement brand from Amyris, Inc. in the U.S. This acquisition aims to accelerate the company’s growth in the women's nutrition and wellness market.

The market is regulated by various authorities, depending on the product category: hormonal, non-hormonal, or dietary supplements. Hormonal therapies, such as hormone replacement therapy (HRT), are classified as prescription medications and are strictly regulated by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), along with similar national regulatory bodies. These products must go through extensive clinical trials to demonstrate their safety and efficacy before receiving approval. Non-hormonal treatments, which include selective estrogen receptor modulators (SERMs) and neurokinin receptor antagonists, are also regulated as pharmaceuticals and follow similar approval processes. In contrast, dietary supplements, such as plant-based or herbal remedies, are subject to less stringent oversight. In the U.S., for instance, the FDA regulates dietary supplements under the Dietary Supplement Health and Education Act (DSHEA). This legislation does not require pre-market approval but mandates proper labeling and ongoing safety monitoring.

Several market players are expanding their business by entering new geographical regions to strengthen their market position and expand their product portfolio. In September 2024, Theramex announced the initial commercial sale of Yselty (linzagolix) in Germany. This treatment for uterine fibroids provides a vital option for females facing significant unmet medical needs. This achievement enhances the available resources in the battle against uterine fibroids, offering females a crucial solution for managing moderate-to-severe symptoms associated with this condition.

Analyst Perspective

The menopause market is benefiting from increasing awareness of menopause-related health concerns, growing acceptance of hormone and non-hormonal therapies, and rising consumer demand for solutions that improve quality of life during hormonal transitions. Product innovations, including hormone replacement therapies (HRT), dietary supplements, vaginal health products, digital menopause management platforms, and personalized wellness programs, are expanding treatment options and attracting a broader patient population. The key competitive advantage will lie with companies that position menopause care as part of a holistic women’s health and healthy aging ecosystem, supported by patient education, personalized treatment approaches, and evidence-based clinical support. By integrating symptom management with preventive healthcare, mental wellness, nutrition, and lifestyle interventions through both digital and traditional care channels, companies can improve patient engagement, increase treatment adherence, and strengthen their competitive position in the evolving menopause market.

Treatment Insights

Based on treatment, the dietary supplements segment dominated the market with the largest revenue share of 94.3% in 2025 and anticipated to grow at the fastest CAGR from 2026 to 2033. Dietary supplements are used by females to help ease the symptoms of menopause, such as hot flashes, night sweats, mood swings, and insomnia. In addition, research has shown a positive role of dietary supplements in the prevention of early menopause. An article published by the National Institutes of Health in November 2023 evaluated the effect of dietary supplements such as calcium & vitamin D and physical exercise on women. The study revealed that a combination of dietary supplements along with physical exercise counteracts various symptoms and lowers the effects of menopause in women.

The over-the-counter (OTC) pharma products segment is anticipated to register a considerable CAGR over the forecast period. The over the counter (OTC) pharma products segment is divided into hormonal and nonhormonal products. OTC hormone preparations are becoming more common among females undergoing menopause. Some of the major products in the segment are Dehydroepiandrosterone (DHEA), ibuprofen, topical progesterone, and melatonin. Growing awareness about the use of hormonal therapies is anticipated to accelerate the market over the forecast period. The non-hormonal products include antidepressants, ibuprofen, naproxen, lubricants & moisturizers, and clonidine (anti-hypertensive). According to NCBI, vaginal dryness or vaginal atrophy prevalent among women undergoing menopause ranges between 62% to 67%. This makes the use of OTC vaginal lubricants and moisturizers common to reduce symptoms. Vaginal moisturizers (Vagisil) and vaginal lubricants (Astroglide and K-Y) are available to help relieve vaginal dryness. 

Regional Insights

North America dominated the menopause market with the largest revenue share of 37.1% in 2025, owing to the local presence of major market players, developed healthcare infrastructure, and increasing prevalence of menopause symptoms in females. A growing emphasis on personalized medicine, early diagnosis & treatment, and rapid adoption of healthcare apps for online consultations of OTC drugs are additional factors anticipated to propel the region’s market further.

U.S. Menopause Market Trends

The menopause market in the U.S. held the largest share in the North America region in 2025. As the millennial population is aging, the country has a large number of women entering menopause; around 6,000 women are expected to enter menopause each day in the U.S. According to a menopause survey of women aged 35 and above conducted in January 2024 by AARP, a U.S.-based nonprofit organization, around 90% of women experience menopausal symptoms that affected their lives as well as work, along with other day-to-day activities.

Canada menopause market is anticipated to register the fastest growth during the forecast period. There is an increase in awareness about dietary requirements, leading to a greater demand for them among older women. Hence, companies are launching several products to cater to this growing demand for dietary supplements in the country.

Europe Menopause Market Trends

Europe menopause industry is anticipated to register considerable growth during the forecast period. The region has a large number of women entering menopause every year, along with a high prevalence of menopausal symptoms such as vaginal dryness. Key players are introducing new products in the market, and medical practitioners are recommending dietary supplements as a healthy alternative to HRT for easing the transition through menopause.

The menopause industry in Germany is anticipated to register a significant CAGR during the forecast period. Germany has one of the strongest healthcare infrastructures in Europe. According to the Statistisches Bundesamt (Destatis), in 2021, around 13.2% of its GDP, i.e., USD 513.034 billion (EUR 474 billion), was spent on healthcare. According to the United Nations Population Fund population data in 2023, 23% of Germans were aged above 65 years, which is expected to increase in the coming years. The increasing geriatric population is responsible for the growing incidence of menopause-related conditions, such as hot flashes, as the symptoms can persist for decades. This opens opportunities for market players to target products to women in older age groups.

The UK menopause market is anticipated to register a considerable CAGR during the forecast period. The NHS has identified the average age of menopause in women as 51 years in the UK, with exceptions that enter menopause before 40 years of age or even in their 30s. It is estimated that around 13 million women, or around one-third of the female population in the UK, are premenopausal or menopausal. Considering the large target population, researchers are innovating products to ease the transition of women through menopause.

Asia Pacific Menopause Market Trends

The Asia Pacific menopause industry is anticipated to grow at a significant CAGR over the forecast period. Large population, increasing awareness about menopause, and adoption of dietary supplements are contributing to market growth. In addition, the market's dynamics are influenced by various factors, including cultural attitudes toward menopause, the availability of diverse product formulations, and the growth of e-commerce platforms facilitating consumer access.

The menopause market in China held the largest share in 2025. The country is witnessing key product innovations by key players, focused on using natural sources for obtaining dietary supplements. In March 2023, Aptorum Group Limited, a clinical-stage biopharmaceutical company, launched a dietary supplement, NativusWell, for use by menopausal women. In addition, Aptorum Group Limited partnered with JD.com, an e-commerce platform in China, for the distribution of its products.

India menopause industry is anticipated to register significant growth during the forecast period. According to a study published by Elsevier B.V. in 2021, the average menopausal age in Indian women is 46.6 years, leading to the early onset of hot flashes. There has been an increase in awareness about women’s health in the country, along with a growing trend of adopting Ayurvedic supplements such as Shatavari for easing symptoms such as hot flashes, as well as Ashwagandha-based supplements.

Latin America Menopausal Market Trends

The menopause industry in Brazil accounted for a major share in the Latin America region in 2025. Technological advancements in the region, coupled with an increase in healthcare awareness, are anticipated to fuel the market. Increasing government spending on healthcare is likely to promote market growth further, as the majority of the population is dependent on government initiatives for pharmaceutical products.

The menopause industry in Brazil accounted for a major share in the Latin America region in 2024. Brazil is witnessing a surge in obesity among women. As per the Global Obesity Observatory, in 2019, obese women accounted for 21% of the female population in Brazil. The rate of obesity is even higher among women aged between 55 and 64. This is directly proportional to the severity of menopausal symptoms such as hot flashes.

MEA Menopause Market Trends

The menopause industry in MEA is anticipated to register considerable growth during the forecast period. Economic development, coupled with high unmet healthcare needs, is fueling the Middle East and Africa market. As per a study by BMC Women's Health in September 2023, the knowledge about symptoms of menopause in this region is average; only 66.8% of women in the UAE admitted to having knowledge about menopause.

The menopause market in South Africa is experiencing the fastest growth during the forecast period. The majority of the aging population in South Africa comprises women who experience menopause during late adulthood. As per an article published by The Conversation in January 2024, around 5.9% of the South African population is over 65 years old. There is a major need to include education regarding menopause and associated symptoms in health programs for women.

Key Menopause Company Insights

Key participants in the menopause industry are focusing on devising innovative business growth strategies in the form of product portfolio expansions, partnerships & collaborations, mergers & acquisitions, and business footprint expansions.

Competitive Benchmarking

Recent Developments

• In January 2024, Bayer AG announced the successful last trial of a menopausal relief drug. The purpose of this drug is to improve sleep and ease hot flashes in postmenopausal women.

• In December 2024, Theramex acquired products such as Duphaston and Femoston from Viatris in Europe (ex-UK). This product acquisition strengthened the company’s menopause portfolio, helping it offer a wide range of treatments for women across Europe.

• In March 2023, Theramex entered a licensing partnership with Radius Health, Inc. This agreement aims to help distribute and commercialize ELADYNOS (abaloparatide) for the treatment of osteoporosis in postmenopausal women in the European Economic Area, Brazil, the UK, and Australia.

• In October 2022, Padagis announced the relaunch of its adjustable dosing spray, Evamist. The purpose of this relaunch is to provide complex, specialized products to patients and customers in the U.S. 

Menopause Market Report Scope 

Global Menopause Market Report Segmentation

This report forecasts revenue growth at a global, regional, and country level and provides an analysis of industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research, Inc. has segmented the global menopause market report based on treatment and region:

• Treatment Outlook (Revenue, USD Million, 2021- 2033)

  • Dietary Supplements

  • OTC pharma products

    • Hormonal

    • Non-hormonal

• Regional Outlook (Revenue, USD Million, 2021- 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • Spain

    • Italy

    • Austria

    • France

    • Denmark

    • Norway

    • Sweden

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

    • Taiwan

    • Malaysia

    • Singapore

    • Vietnam

    • Hong Kong

  • Latin America

    • Brazil

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The menopause market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each menopause segment quantified using the revenue-capture definitions in the table below.

Segment Definition

Estimation Model

Commodity Flow Analysis

The research methodology is divided into a two-tiered approach the commodity flow approach for estimating the market size by analyzing product-based revenues from notable companies, followed by the volume-price approach for market validation. Below is an overview of each approach and the methods applied for regional and country-level forecasts.

• Regional and Country-Level Share Estimation

• Volume-Price Approach (Market Validation)

  • To validate the market size obtained through the commodity flow approach, we employed a volume-price approach. This approach involved the following steps:

    • We identified the target population for menopause-related products as women aged 45 to 55 years across the defined regions.

    • Penetration rates were estimated by analyzing the proportion of the target population opting for alternative therapies, based on secondary data, healthcare studies, and regional therapy trends.

    • The average cost of OTC menopause-related pharma and dietary supplements was calculated, factoring in regional price differences.

    • We then calculated the market size by multiplying the estimated target population by adopting alternative therapies with the average cost of products.

• Commodity Flow Approach

  • To derive market size, the commodity flow approach was used, which involved analyzing the revenue contributions of key players across the OTC pharma products and dietary supplements segments.

  • We identified leading companies in the menopause market and analyzed their revenue data specific to OTC menopause-related pharma and dietary supplements.

  • To estimate a country’s market, we studied the product demand by assessing their annual revenues.

  • Bayer AG, Theramex, Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Abbott, Pure Encapsulations, LLC and Dr. Reddy’s Laboratories Ltd contributed significantly to the total country-level market.

  • The market value was obtained by studying annual reports, regional presence, R&D innovation, regulatory status, and financial performance.

  • The estimated market share of each company was based on several key parameters, including:

    • Product portfolio: Number and variety of products targeting menopause symptoms.

    • Pricing strategies: Pricing variations across different product forms and channels.

    • Distribution network: Access and penetration across offline and online retail channels.

    • Sales Data: Available sales data from reports, databases, and company disclosures.

  • Using revenue data and market share estimates, we derived the market size for each segment. The sizes of the OTC pharma products and dietary supplements markets were then summed to reach the total menopause market size.

• The regional and country-level shares were estimated by segmenting the menopause market according to:

• Demographic and Healthcare Trends: Consideration of healthcare trends and demographic factors such as population aging rates and lifestyle factors that impact menopause product usage.

• Economic Indicators: Regional economic factors such as GDP, consumer spending, and disposable income levels were factored into the regional segmentation.

• Regulatory Environment: Regulatory differences impacting the availability and popularity of OTC pharma and dietary supplements were considered, particularly in regions with varying levels of restriction on menopausal product claims.

• Forecasting Methodology

• Market forecasts for each segment and country were derived based on:

  • Historical data analysis: Examining historical market trends within each segment and applying growth projections to estimate future trends.

  • Consumer demand patterns: Projected changes in consumer preferences and demand patterns for menopause-related products.

  • Technological and Product Innovation: Analysis of upcoming product innovations, formulation improvements, and shifts in product availability.

  • Macroeconomic factors: Economic forecasts at the regional and country level, including projected changes in population demographics, healthcare expenditures, and economic growth.

Delivered Customizations

This report has been delivered with the following In-depth customizations